Analysts Set Repligen Co. (NASDAQ:RGEN) PT at $196.70

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $196.70.

Several analysts recently issued reports on RGEN shares. KeyCorp increased their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. increased their target price on Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. Finally, Stifel Nicolaus increased their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd.

Repligen Stock Down 1.3 %

RGEN stock opened at $164.17 on Friday. Repligen has a 1-year low of $110.45 and a 1-year high of $211.13. The business has a fifty day moving average price of $191.57 and a 200-day moving average price of $173.25. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75. The stock has a market capitalization of $9.17 billion, a P/E ratio of 228.02, a P/E/G ratio of 5.62 and a beta of 1.02.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen’s revenue for the quarter was down 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.68 earnings per share. Equities analysts forecast that Repligen will post 1.46 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock valued at $5,039,532 in the last ninety days. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently modified their holdings of the business. Fortis Capital Advisors LLC bought a new stake in shares of Repligen during the 4th quarter worth approximately $35,000. Park Place Capital Corp increased its holdings in Repligen by 90.2% during the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 120 shares during the period. Benjamin F. Edwards & Company Inc. increased its holdings in Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 146 shares during the period. Signaturefd LLC increased its holdings in Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 86 shares during the period. Finally, Principal Securities Inc. purchased a new position in Repligen during the 4th quarter worth $48,000. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.